SynthesisFrontiers in immunology2026
Hypoxic cancer stem cell-immune niches in the tumor microenvironment: a Systematic Review of mechanisms and therapeutic implications.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hypoxia, cancer stem cell (CSC) plasticity, and immune suppression are established features of the tumor microenvironment, but their integration within the same biological systems has not been comprehensively synthesized. This systematic review evaluated whether hypoxia or hypoxia-associated signaling coordinates CSC or stemness phenotypes with immune-related mechanisms. Methods: PubMed, Embase, Scopus, Web of Science, and Google Scholar were searched for English-language studies published from 1 January 2010 to 31 January 2026. Eligible studies were required to evaluate hypoxia or hypoxia-associated signaling, CSC or stemness phenotypes, and immune-related outcomes within the same experimental or translational study. Of 1,569 records identified, 39 reports underwent full-text assessment and 14 studies were included. Results: Hypoxia-associated conditions were recurrently linked to CSC enrichment, self-renewal, epithelial-to-mesenchymal transition, tumorigenicity, metastatic potential, immune suppression, and therapeutic resistance. Four context-dependent patterns emerged: impaired natural killer, cytokine-induced killer, and CD8-positive T-cell function; myeloid- and macrophage-mediated reinforcement of CSC states through polarization, cytokine signaling, extracellular vesicles, cellular transfer, and stromal or vascular remodeling; checkpoint-associated and adaptive immune suppression involving PD-L1, CD47, regulatory T cells, and myeloid-derived suppressor cells; and an integrated hypoxic CSC-immune niche phenotype. Preclinical intervention studies indicated that selected pathways may be therapeutically modifiable, although the evidence remained predominantly experimental. Conclusions: Hypoxia appears to act as a coordinating microenvironmental pressure linking CSC plasticity with immune dysfunction in selected tumor contexts. The proposed hypoxic CSC-immune niche is a mechanistic framework rather than evidence of a universal pathway and requires validation using spatially resolved human tumors, patient-derived immune models, and treatment-response-linked cohorts. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261287704, identifier CRD420261287704.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.